Where we share our weekly news debriefs and discussions with industry experts. These are lo-fi recordings aimed at giving our readers more opportunities to engage with our analysis and a view into some of the conversations that shape it.
Martin: So htn, nerd.ai,
new, so excuse me, new nerd.ai.
You're thinking about
pivoting the company.
Kevin: I am.
You know, I saw how well the pivot went
for, uh, our favorite shoe manufacturer
last week, and I figured, why not us?
That seems like a good idea.
I know about as much as GPUs as the next
person who knows nothing about GPUs.
So.
We should be able to execute
on this pivot, right, Martin?
Martin: Well, we're missing
a couple key ingredients.
I don't think that this is, you
know, deal breakers, but number one,
Allbirds has a, a public ticker.
True.
Which helps them sort of,
you know, raise the money.
And number two, uh, there's like
a sort of, I think, a lot of
affection for Allbirds in the Valley.
I think everyone, you know,
has fond recollections.
Not that, are you
Kevin: applying, there's not affection
towards health tech nerds in the Valley?
Martin?
Martin: I think it's,
I think it's different.
I think it's just a different, uh, a
different connection that folks have, but.
The, the financing structure.
We, we should get Sean on to
talk about this at some point
'cause it is kind of interesting.
But the financing structure here is funny.
So like an investor does something
called a Death Spiral convertible
where they all, it's literal,
Kevin: they call the
Death Spiral convertible.
Martin: Well, I don't think that
Berg, that's the investor would call
it, but that's what people call it.
Kevin: Yeah.
Martin: And basically what it does is
they, they, they issue these convertibles
and they're allowed to convert at a
price that is lower than whatever the
current market price is for the stock.
Kevin: Okay.
Martin: Not at a set price
like most convertibles, but
at a price that is just lower.
Kevin: Whatever is lower
than the current price.
Yep.
Martin: Yeah.
And so they can convert whenever
they want and sell stock
and then keep on doing that.
And the reason why it's called the Death
Spiral convertible is because eventually
you convert into a couple pennies.
And
Kevin: that makes sense.
Martin: Yeah.
Kevin: It, in, in many ways reminds
me of the conversation we had a few
months back about the, uh, failed
biotechs becoming shell companies
for, um, as bitcoin treasuries, like
you, you have a public ticker and
therefore shenanigans ensue when your
business isn't going as anticipated.
Uh, I don't know.
Martin: That's pretty much exactly it.
So it is almost the top of the hour.
We've got an incredible show today.
We're talking with Neil Shaw
about the great unbundling
of maternity care CBT codes.
We're talking about alternative plan
design with Russell and Will from Yuzu.
We're talking to Shiv from
Abridge about their new expansion
into clinical decision support.
And then Patrick Shehan from Withings
about access and connected devices.
But first.
Um, at the top of the show, we
got some stuff to talk about in
terms of the news of the week.
Kevin, do you wanna kick us
off by talking about this great
highlighting job you did for access?
Kevin: A lot of skill went into this one.
Um, yeah, access last week,
obviously top news from the week.
You and I both covered this in newsletter.
Um, the initial list of 150
ish participants came out
Monday afternoon by CMMI.
I found it fascinating to go back
to the, um, the original launch
event, which was what, late 2025
when we were talking about that.
And this slide that we've got up
on screen, which highlights the,
I think it was 68 ish initial
participants in that list.
And what immediately jumps
out to me, Martin, is there's
a lot of red on this page.
It seems that a handful of the digital
health companies that evaluated
the access opportunity looked at
the rates after they came out.
'cause that was kind of the big difference
between that and today, right there.
The, the concept of this program, the
outcomes based payment, the excitement
around that doesn't seem to have changed.
But what has changed is companies have
seen what the rates are and seemingly
said this is too low to operate in.
We're gonna dig more.
Martin: Go ahead.
Oh, yeah.
Yeah.
I was just gonna ask,
what do you make of that?
I, I think like the, the talk track
we've heard sort of memorably,
Chris Klo said, we're not gonna let.
This incredible technology,
AI pile drive or healthcare
pile, drive it into the ground.
Mm-hmm.
What do you make of the fact that, you
know, I mean, 150 is not nothing, right?
That's a, that's a lot of people,
but that so many of the original
interested parties said, no, thank you.
Kevin: I, I think it's indicative of
the change that CMMI is trying to drive.
And the question mark that's
still out there on whether
or not they can do it, right.
Clearly they've got companies
raising their hand saying,
we're interested in this.
We're gonna talk with
one of 'em later today.
Um, in Withings, I'm curious to see
how they evaluate o the opportunity,
so the opportunities there, the
interest is there from these companies.
It's worth noting that they haven't
committed to anything yet by, by
applying and indicating that they
wanna participate in the program.
Right.
This is not a commitment.
So they could still, I don't know
the exact mechanics of this, but my
understanding is they can still opt out
before the program starts on July 5th.
So it.
It's indicative of the gap I think that
exists between if you're CMMI trying
to drive this change and implement
this, this new payment model, and
you're the digital health industry.
The digital health industry as I
understand it, is looking at these rates
and building up financial models and
saying, Hey, based off the way we think
about this, we can't make this work.
And at the same time, CMI is saying,
well, we want you to think about it
differently and actually build a new model
that doesn't build from the ground up.
And to me that like that's the most
interesting element in all of this
is you've got, going back to what
Clump and others say about this,
like CMI has been pretty clear in
my mind that you're gonna need to be
an insurgent to win in this model.
You can't think like an incumbent
building backwards from what exists today.
You've gotta rethink the whole model.
And I don't think anybody would
call the digital health industry
the incumbent class in healthcare.
That's kind of the
implication, isn't it, Martin?
Martin: Yeah, I, yeah, I, I've been
thinking about this a lot lately,
and I think it's, you know, pre it
would be premature to say, okay,
CMS said AI is this potentially
transformative technology?
We're going to put that up, we're gonna
call your bluff and say like, if, yes,
if you can deliver care at very low
marginal costs, you can win with access.
We're gonna actually pay you a lot.
If your, if your marginal cost
is close to zero, then a lot more
people should do raising their hands.
And so I, I, I think it would be
premature to say like, well, this
proves that AI can't deliver care
at marginal zero marginal costs.
Um, but it does raise a question for me.
Kevin: Yeah, for sure.
I, I mean, I, we have
heard that narrative a lot.
I, I, I think we've both expressed
our skepticism towards that narrative
over time, and I think this reaction
embodies that skepticism, right?
It's like, okay, CMS is in, is in some
ways asking the industry in my mind to
put their money where their mouth is and.
Drive this change.
And the industry has said, guys, we
can't, we can't do it at these rates.
Which I, as I understand, like
there, there's, there's good reason
why they're opting out, right?
Like you look at the, the build cost
and between the cost of acquisition
of patience, between the cost of
procuring devices that you need to
send out and whatnot, the cost of
actually even just AI phone calls.
Like there, there's a stack of costs
that these companies would still need
to incur to operate these programs
that are, that are not nothing.
And then on top of that, as I
understand it, there's some, there's
some policy nuance in this too, of
how the payments actually flow and
some of the potential concerns of, um.
If you're participating in the program
and you're expecting payments from the
program and somebody else is participating
in traditional fee for service model,
like what happens if another company comes
in over the top to take that patient?
Have you just invested and, and
you're not losing those costs?
So as I understand it, there's some
of those questions too that presumably
will get worked out over time, right?
Like as I've heard it from CMMI,
they recognize that there's, this
is a model that will change in time.
If that's a big risk, I would
think they would address that.
Right.
Martin: I'm pretty.
I remain of the opinion that access is
an incredibly cool thing for our federal
government and CMMI to be trying out.
It's a great experiment, which is can you
deliver care with very low marginal costs?
Historically, the answer to that
question has been a resounding no.
And it's cool that you know, I
mean, we'll see how many of them
actually start participating, but 150
people raised their hand and said,
yeah, we're gonna go give it a try.
Kevin: Yeah.
Martin: I don't know.
I, I,
Kevin: I think you and I, I think
we're both in the camp of you wanna
see this program succeed, right?
If, if AI is really gonna bend
the cost curve, this programs
like this have to work, right?
Like, it, it, it, it can't be the
answer that this access doesn't
work 'cause rates are too low.
Maybe there are iterations of it that are
needed to come, but like it has to work.
Um, so I'll be cheering it on for sure.
Martin: In the newsletter.
I talked about my favorite
Gallup poll from a decade and a
half ago, which, you know, says
like, Medicare is a increasingly
high percentage of the budget.
Would you prefer reducing taxes or sorry,
raising taxes or reducing benefits.
And like overwhelmingly the American
people say, no, we would prefer you
didn't do either of those things.
And to me, access is like one way
to get out of that choice, right?
If you say we don't wanna reduce
benefits, we don't wanna increase
taxes, like you need something
like a transformative technology
to really make this thing possible.
And so that's, that's why I'm, I'm kind
of crossing my fingers for it, but it is
hard to do and probably we will have to
raise taxes or lower or reduce benefits.
Kevin: Yep.
So start with the trade-offs.
Martin: Talk to me a little bit
about your peptide stack these days.
Kevin, you're doing, you're doing
the Wolverine stack, I think
is what you, you were sharing.
Kevin: I, I, I would say I'm still in
the contemplation phase of whether or not
I should be doing the Wolverine stack.
I cannot say that I have, um, uh, partook
in the Wolverine stack, I suppose yet.
But yeah, that was one of the other
big headlines from the week on, I
think it was Wednesday afternoon.
This wasn't a surprise to folks
following the peptide space, but the
FDA came out and said they're gonna
start the process of, um, considering
whether or not they will ease, uh,
the regulations around peptides.
In part, this, you know, RFK has been
signaling this seemingly for a bit now.
The gray market around acquiring peptides
from Chinese manufacturers is a concern.
And I suppose if instead you manufacture
them here in the states, uh, and have a,
what is it, a green market, I suppose,
uh, for peptide manufacturing that
you can keep an eye on better through
compounding pharmacies and whatnot, that
is a better outcome for that space there.
You know, if you read the headlines from
it last week, there's some concerns about
whether or not this is gonna encourage
this kind of wild west behavior in
gold Rush towards the peptide market.
Seems like we're pretty clearly
headed in that direction regardless
of whether or not it is wild
west or this is a good thing.
I don't know.
We're all gonna find out over
the next coming months, years
in this general landscape.
So, uh, it's gonna be
interesting to keep an eye on.
The one thing I do know is that
investors and entrepreneurs are seemingly
gearing up for this opportunity as
peptides go mainstream in this country.
HIMMS stock, I think, was up 50%
last week, just starting after the
news came out Wednesday afternoon.
Um, clearly investors are excited about
the opportunity for it to leverage
peptides as its kind of next phase
of growth, uh, for the business.
Superpower came out, I think it
was Friday afternoon, and announced
that they've got their wait list.
So if you're looking to um, uh, get
in on the peptide craze, you can join
their wait, wait list as they, uh,
prepare their product for launch.
There's a company called Protocol,
I think it's pronounced Protocol.
Protocol with a e at the end of it.
Is that how you think you pronounce it?
Yes.
Um, they came out with a more
clinical grade model for peptides.
Uh, they raised, um, seed
funding and came out of stealth.
And interestingly, and this is like, this
is where I find the space fascinating.
A in a sign of maturity of it, ultralight,
which is an EHR platform for longevity
clinics kind of peptide space adjacent.
They came out and raised $9.3
million.
They used to be known as Vibrant Practice.
It's being used in 75 longevity clinics
today, which to me is indicative like when
you see the derivative plays of a market.
Like an EHR for longevity clinics, raising
that sort of capital, it is indicative
of the market opportunity that investors
are looking at as they build their
spreadsheet saying, okay, this company is
going to offer this for these 75 clinics.
The math you gotta do on the number
of clinics and the offering for
an EHR to get into that space, it,
it's indicative that it's, they're
expecting it to be a big market.
Martin: Moving on from peptides,
Brendan Keeler and the HTN Slack shared
a study, looked at New York City or
New York state providers and found
after the implementation of price
transparency, you're not gonna believe
this providers raised their prices and No.
Yeah, I know.
Uh, that's not supposed to happen.
It.
It very quickly escalated into a
conversation about, uh, Danish concrete.
Are you familiar with the
Danish concrete study?
Kevin: I, I, I've heard you
reference it before, but share
for the community who hasn't
Martin: heard it.
Well, it's just great.
Okay.
So, uh, if you're a huge nerd, you,
you think about Danish concrete a lot.
So, uh, the, the concrete market in
Denmark is pretty concentrated, and
in the late eighties, the Denmark
basic Denmark basically said, we're
going to require price transparency
for concrete manufacturers.
One of the things that they didn't
really, you know, on the assumption that
it'll make the market more efficient.
Kevin: Mm-hmm.
Martin: And.
One of the things they didn't really
think through is that it's actually very
hard to like ship concrete across the
country of Denmark or, or really anywhere.
You kind of need to go to your
local concrete provider for that.
And there's basically all monopolies.
And so if you have a monopoly and you
make prices transparent or a quasi
monopoly, everyone just kind of starts
raising their prices a little bit.
It allows you to collude without,
you know, breaking the law.
And so there's this famous
paper talks about basically,
you know, here's the market.
It was really concentrated, whoops.
Prices went up.
And this is something you and
I come back to all the time.
There's a lot of folks who say, man,
if we just had transparent prices,
things would be so much better.
And there's really not
good evidence for that.
It wouldn't hurt if we had
hyper competitive markets, but.
Most hospitals in most states are kind of
in their own little monopoly or there's,
you know, one or two other options.
And if you make prices transparent,
they're just gonna, you know,
raise their prices.
Kevin: Yeah.
I, I think there's enough evidence at
this point of price transparency coming
in, prices going up, uh, no surprises
act being another example of that,
that we've seen, certainly that I've
come to expect that to be the case.
Not to say that I think price
transparency is a bad idea.
Like, I think both of you and I would
agree, price transparency should be
in these markets, but it alone isn't
going to drive costs down in healthcare.
You need to couple it to your
point, with a whole smorgasbord of
other changes in these markets too.
I, I, I.
I would think,
Martin: yeah, there's really
never one weird trick that doesn't
involve something painful or,
Kevin: but wouldn't it be easier if there
was Martin, like I just, I, I want the
one thing we need to give Mark Cuban
his one talking point that is magically
going to allow us to fix healthcare and
price transparency feels like a good one.
I don't know the prices.
Damn it.
It's confusing.
Martin: If you are interested
in seeing or watching a fight on
LinkedIn start to develop, you
can go to Kevin O'Leary's LinkedIn
where he's calling out Mark Cuban.
But before we get too into
that, one of the things that.
Thematically has come up Last week
when we were talking to Andrea from
Simply Fed is the great unbundling.
And this is a fascinating topic to me.
It's a fascinating topic
for a bunch of reasons.
Kevin, while I bring our guests
forward, can you tee us up for
this conversation a little bit?
Kevin: Yes.
Um, I must admit, I, I felt
pretty oblivious to this
topic even two weeks ago.
And then I read a blog post from Neil Shaw
who's joining us here, who started talking
about this great unbundling of maternity
care and the transformation that's
happening from a payment rate perspective.
Kind of going from value-based
care bundle payment concept to more
old school fee for service type
mindset in the maternity space.
Neil, really excited to have you on today.
Uh, excited to learn more about what's
happening in maternity space and wanted
to see if you'd just start us off with.
Historically, what's up with this
bundle payment and maternity care?
What, what drove this change today and
what should folks looking at the space
expect to happen over the next kind of
coming 12 months, 24 months and beyond?
Neel: First of all, I need to hang
out with you guys more because,
uh, anybody who's like, there was
a paper once on price transparency.
He's like good friends with me.
But, um, yeah, so historically, uh, now
we're talking like for a full generation,
going back like 40 years to the eighties,
uh, the way maternity care was paid for
the United States was this one big bundle.
And, you know, healthcare is complicated.
We've had this idea of bundles,
uh, for a while, but particularly
following the Affordable Care Act as
a way of paying for value, whether
it's a joint replacement or even some
kinds of cancer, uh, um, services.
And then the notion is if you,
you pay for a whole episode of
care, you're less likely to get
the fee for service incentives of.
You know, getting paid to
utilize more than you need to.
And pregnancy and maternity care is
like one of the most bundle able things.
It's got, you know, a starting
point, an end point, um, you know, a
pretty predictable set of services.
Uh, and for a long time that
bundle seemed to serve its purpose.
Um, and we can get into it, but, um,
I also kind of saw this innocuous
email from the American College of
OB GYN, uh, a few months ago, saying
that the bundle was gonna end.
Um, and it seems like this really
wonky technical change, but it will
actually change the way maternity
services are not only paid for, but
delivered, uh, for the next generation
of people, pretty substantially.
Martin: Can you give us a peek into
the future of like, what this is
gonna look like practically if you are
having a baby or happen to be a clinic
that does maternity care like Maven?
Neel: Sure.
I mean, maybe let's start with like
the why, like why are they changing?
I mean it, the, this was one of the,
again, one of the fears of healthcare
where, um, where there, where you are
a purchaser or just a person having
a baby and trying to start a family,
there's a very predictable way of
paying for care for the most part.
Um, but the bundle was starting to get
stressed by the fact that in 2026, the
doctor you see in the office is rarely the
doctor that delivers your baby anymore.
That used to be most of the
time, and now it's like pretty
rare for that to be the case.
And so that creates complexity around who
should get paid what within that bundle.
Um, so team-based care change things.
And also, uh, technology has changed
radically in the last 40 years.
You still can't deliver
a baby through a screen.
There are some limits, uh, when it comes
to maternity care, but, you know, the
first ultrasounds used in pregnancy
was when I was born, uh, and I'm 44.
Um, the first IVF baby in
the US is the same age as me.
So, you know, and, and that doesn't
say anything about, you know, genetic
screening and a, a lot of the more
advanced therapies that we have today.
And so the bundle didn't do a
great job of accounting for that.
Uh, and so a lot of people said that
it was stifling, uh, innovation.
Um, nobody knows exactly what's gonna
happen when we fully unbundle, but the
decision was made, um, that we're just
gonna pay for things piecemeal now.
Um, and, uh, in the process of
reporting on this, I talked to, um,
the, the CPT committee at the A MA.
Uh, I talked to payers, I talked
to clinicians on the ground.
Um, and one, it's, it's
designed to be budget neutral.
So the a MA does this and they
go to CMS and they tell them
it's a budget neutral change.
But that means that, uh, you're
gonna pay more in some places
and less in other places.
And that's where the rub comes.
So if you're, you know,
you take care of high risk
pregnancies, you'll get paid more.
If you have a high risk pregnancy, you'll
pay more or somebody will pay more.
Um, and probably what'll happen is if
you have a low risk, straightforward
pregnancy, um, the payments will go down.
Uh, and that has implications also.
Kevin: Neil, when you say the payments
will go down, this is the question I was
gonna ask you kind of, you know, squeezing
the balloon concepts, I hear the theory,
a lot of somebody's gonna get paid less.
And one of my lessons learned getting
into healthcare innovation over
the last decade is that doesn't
seem to materialize all that often.
How, how are costs gonna go down?
Is it, is it rates go down for
the low cost for the, the lower
risk pregnancies, or what's Yeah.
What's driving that shift?
Neel: I mean, so I'm told that,
uh, we're full steam ahead.
This is happening on January 1st, 2027.
There are a lot of, um, open questions
around implementation and there's
a lot of additional guidance that I
think we're meant to be getting around
modifiers and things like that, Kevin.
Yeah.
Um, but you know, like part of
my role at maintenance to guide
purchasers and what they should expect.
Um, and uh, part of what we're aiming
to do also is plug access gaps.
Um, and one of the people I interviewed
along the way, um, is Ris Bakari,
who by the way, you should have on,
'cause he's imminently quotable.
Um, but you know, he's got a company
called Claimable and he's really on
the front lines of American frustration
with the American billing system.
Uh, and one of his better quotes
that he gave me is, uh, he called
unbundling the original sin.
And he was like, you know what happened
when they unbundled your cable?
Did prices go down to your point, Kevin?
No.
No, they did not.
Now I pay for five streaming services
where he was like, remember the quaint old
days when you just paid for airfare and
also covered your meal and your baggage?
It's like, how does it work now?
So, I mean, I think, um, ultimately
for a lot of, uh, purchasers and a
lot of people, prices will go up.
My my worry though is that, um,
particularly in rural America or you
know, independent practices that we're
already serving people with really
marginal, uh, or really thin margins,
um, the incentive to take care of
lower risk people might go down, right?
And so they may shift to make more money,
but the fundamental, uh, truth is that
if you are a straightforward person,
um, your pregnancy will cost less.
Martin: I am curious about your
view on how, so I, I hear the
argument that he's making about
unbundling being the original sin.
You know, the, the sort of rejoinder
to that is like a lot more people
fly today than could fly when
everything was bundled together.
Um, the question I have coming from
the kidney care space is bun, like the,
the bun kidney, the bundled payment
for kidney has done a incredible job
of keeping dialysis payments low.
But it's also, I think,
stifled a lot of innovation.
And I'm curious what you are
seeing as like, what are.
Folks in the market missing out on because
it just doesn't fit into the bundle.
Neel: What a time to be alive, Martin.
I mean, like right now we live in a moment
where, uh, you know, preeclampsia has
been a scourge for humanity since forever.
Uh, like it's an ancient Egyptian text
as this thing that kills pregnant people.
And even today it's one of the really,
really, yeah, we have, we have, we
have, uh, tens of thousands of years
of, of history, basically since there's
written language, we're describing
this mysterious disease of pregnancy.
And until, basically today
we had no idea what it was.
But now we can, uh, use free
floating mRNA that's in the maternal
bloodstream, uh, from the fetus and
identify someone who's gonna get
severe preeclampsia months before
they do with no apparent risk factors.
Um.
Okay.
That's one of like a million examples
I can give you, uh, or a ring, uh, you
know, is really good at sensing thermal
shifts, which happen right around the
time of ovulation, but also it happens
right before people go into labor.
Uh, and when I was on call, uh, in the
hospital, the only way I knew if I was
gonna be busy is if there was a full moon.
But now we live in a world where
maybe we can predict labor onset,
something that I thought was
impossible for my entire career, right?
So there are all of these emerging
technologies that have not translated
into routine practice because we
haven't had a construct to pay for it.
And I think it's a totally reasonable
argument, um, that the old bundle,
uh, was stifling innovation in a way.
The question is whether we should
have thrown the baby out with the bath
water and whether there's a better
bundle, um, at least as a concept.
Um.
But, uh, it's, it's a, it's
a totally fair question.
I think that, um, you know, the
expectation is that, uh, certain
types of innovation will be easier
to bring to market this way.
Kevin: Neil, one of the things I think
I read in the article was that, um,
it was kind of this point of bundle
of stifling innovation and that
removing this bundle will actually
allow for more innovative payment
constructs to come to fruition as well.
Uh, I'd be curious if you could, uh,
expand on that statement a little
bit, and also what you're seeing.
What are the implications for the
employer market more broadly speaking
for a company like Maven working with
employers to manage maternity costs,
like I would, I would think that's
where some of the opportunity now lies
to rethink what a bundle is there.
How are you guys processing this and
thinking about the opportunity in, in
new forms of alternative payment models.
Neel: Well, I mean, I think the one
thing that we're certain of is that
there'll be more uncertainty, right?
And basically, like the nerdy way
of talking about it is volatility.
Kevin: Yep.
Neel: Um, right.
And, and wherever you see volatility,
there's an opportunity to think
creatively about risk and risk management.
So it's possible that there could be
a world where you see, uh, you know,
willingness to take on risk in different
ways now that there's more volatility.
Um, there are some purchasers that we
serve at Maven that have a baby every
12 minutes somewhere in the world.
Um, and, uh, you know, a lot of them skew
towards higher risk, and we are projecting
that they're gonna see higher total costs
of care as a result of the unbundling.
And so it argues for.
Stronger and more
effective care management.
Um, one of the things that I'm excited
about with the unbundling is that we'll
have much more granular information about
the services that are being provided.
'cause people are gonna be
billing at the service level.
Um, and you can't fix what you can't see.
Um, and so we'll have much
better visibility into services.
And so theoretically, I think like you and
Martin were talking about this, uh, right
when I came on, but like, you know, price
transparency by itself isn't good enough.
Kevin: Mm-hmm.
Neel: I think Abraham Verghese once
said, if you're o ordering off a menu
that has no prices on it, it's really
easy to get the filet mignon every time.
You know?
And so like conceptually,
price transparency should
help, but you need some kind of
accountability mechanism with it.
Right.
And I think those are where a
lot of the open questions are is
like, okay, we'll be able to see
which services people are getting.
We'll probably have a point of view on
whether they're the right services or not.
But then what is the accountability
mechanism to sort of make sure
that we're course correcting?
Martin: I'm, you know, an, an
absolute tourist in this area.
I have a 10 month old.
But aside from that, no real sort of on
the ground, uh, uh, research expertise.
I used to work for Medicaid though,
and one of the things that I find
amazing is, you know, Colorado
Medicaid, they have this doula program
and the results are like incredible.
It seems to me like doulas are one of
those things that are maybe like under
reimbursed today and in a new model we
can that, you know, that, that, that
sort of takes it out of the bundle.
Are there anything that you are
sort of excited to see in terms
of technology or process or care
management that you think is gonna be.
Better compensated going
in in this new paradigm.
Neel: Uh, first of all, I love that lead
up because I mean, having a 10 month
old gives you plenty of street cred.
'cause I, I delivered thousands of babies
before I had to take one home, you know?
And I feel like that really
changed my perspective, uh,
but then casually dropping that
you also worked for Medicaid.
But, but I mean, listen, uh, I think
that doulas are an example of the
only public health intervention that
consistently works for everything, which
is the community health worker, right?
Whether it's directly observed therapy
for tuberculosis in Haiti, or like
cholera treatment or, you know,
like community health workers work.
And there's a ton of evidence.
And I think that there's also a lot
of momentum for state Medicaid systems
to reimburse, uh, for doula services.
Um, I think 26 states now and
growing and that is great.
And also, you know, Medicaid
works from a scarcity.
Mindset and reality.
Uh, and so doula reimbursements,
crowd out other services.
And fundamentally the challenge is
that, you know, childbirth is one of
the highest value services I would
argue that our health system provides.
Um, but we don't pay for
it the way we value it.
We pay much more for, um, end of life care
in the ICU or, you know, other things.
And, and it's hard to, you know,
like all of our health services are
valuable, but relative to the way I
think society ought to value childbirth,
um, we probably, um, don't do a good
job of paying for all the services that
people would benefit from, including
doulas, but including everything else.
Martin: I appreciate the
dots and partners in health.
Shout out.
Uh,
Neel: yeah.
Well, it's a nerdy, it's a nerdy
podcast, so I figured I'd go there.
Martin: Yes.
Kevin: Neil, I'm curious on the
awareness front, uh, how you see this
playing out over the coming months.
I, you know, as health tech nerds,
I like to think that we keep our
eye on stuff that's happening.
Certainly, it's, I'm so proud of
Neel: myself scooping you.
Kevin: Yes.
We appreciate that.
Yeah.
That is how we learn
in the Slack community.
Um.
It strikes me that I, I, I imagine
most employers aren't aware of this
change or haven't fully processed it.
Brokers are still in a processing
phase of the change at hand.
I was reading an article this week
talking about what employers are
thinking about in terms of managing costs
and its alternative plan designs and
transparency and, uh, primary care models.
How, how big of a deal is this gonna be
for employers, for the large employers
who are having a birth every 12 minutes?
Um, are they gonna, would you expect
that come 2027, this is gonna be
rising up the list of, Hey, we need
to think more about maternity now
that this change is coming to play?
Or what's gonna be the impact
among employers and how should
brokers be thinking about that too?
Neel: This is gonna be a slow burn story.
Yeah.
So the story is not over,
like, this is like ground zero.
We're pointing out that this is happening.
Um, I think, uh, more smart
people like yourselves are
gonna start paying attention and
weighing in as we learn more.
And then, you know, uh,
CMS is gonna spend years.
Studying what happens, uh,
and theoretically making
adjustments accordingly.
But I will tell you, um, in, uh,
effectively breaking the story open, um, I
have never seen more interest in anything
that, uh, we I've ever tried to talk
about, um, from the purchaser community.
'cause this wasn't on a
lot of people's radars.
Even, uh, you know, the health plans
have to update all their systems.
Yeah.
Um, there are practices on the
ground that, uh, are just beginning
to contemplate what this means.
And some are projecting significant
revenue shortfalls as a result, and
others are counting on being winners.
Um, so there's, there's
a lot I think that, um.
We're likely to learn, but I think
it's possible that, uh, some purchasers
of healthcare whose population
skew towards being higher risk will
see cost increases of up to 10%.
And it's not just the folks who
have a baby every 12 months.
If you were to take the entire GDP
of the United States and spread
it out across a table, you could
see the cost of hospitalizing moms
and babies with your naked eye.
It's 0.6%
of our whole GDP.
It's the most utilized healthcare.
It's 25% of all hospitalizations
are a mom or a baby.
Um, so if you're a Medicaid system
in Colorado, or if you are, you know,
um, a commercial purchaser or a union,
everybody's gonna see and feel this.
Martin: Yeah.
Neil, we're at time and
unfortunately can't keep you longer.
We didn't get a chance to talk about
Mavens expansion into fertility, so we'll
have to have you back or expansion of the
fertility and family building programs.
Excuse me.
For folks who haven't read it yet, if
you go to maven preprint.substack.com,
you can read The Great Unbundling by Neil,
which is what prompted this conversation.
It is very fascinating.
Neil, where can folks learn more
about Maven and get in touch with
you if they, if they want to?
Neel: I think Substack is a great spot.
Um, I think, uh, you know, it's
a, it's this wonderful medium
where people like to read.
Um, and so you can write a 5,000 word
long form article about the great
unbundling and have people pay attention.
Martin: And we are, uh, we really
appreciate your time today.
Thanks so much, and like I said,
we're all, we're already looking
forward to having you back.
Neel: You bet.
Thanks Destiny, Danielle.
Martin: So.
I thought you teed it up nicely as a sort
of transitional topic on this question
about what does this mean for employers?
Like the, the dominant thing that we
hear whenever we're hearing anything
today is about how squeezed employers
are when it comes to healthcare costs.
Mm-hmm.
And
this, this feels like a real sort of
punch in the teeth in terms of like,
well, we are, we're taking your, one of
your highest cost things and we're gonna
unbundle it and make it even higher cost.
Kevin: Yeah.
And like, can you imagine being HR team
at employer, you're, you know, you're
trying to wrap your arms around what
you need to be doing, the programs
you have in place, and then all of a
sudden some group decides that maternity
care in this country, like 1, 1 27,
we're changing how we pay for it.
Surprise guys, have fun.
Like, go figure it out.
Like I just, conceptually it's.
It's so wild to me.
Like it's, it's crazy.
Neel: Yeah.
Kevin: And ultimately, like, you know, we
talk about the iron triangle all the time.
I, it, it seems like this is playing
out in real time in front of us.
You can like see the calculus, Hey,
we are improving access and quality.
Um, and it might cause these issues for
cost because cost might go up, right?
Like I, you know, these trade-offs
are, but if costs don't go up because
we have a balanced budget perspective,
somebody's getting paid less.
And Neil articulated the concern
if somebody is getting paid less,
that has implications for low
risk rural pregnancies, right?
Access might be shut off for those and
like you can just, you can see it in
real time, which I, I find fascinating.
Neil's point on that being a slow burn.
It's, um, gonna be interesting for
us to watch over the coming years.
Martin: This is one of those things where
forever I thought, thought of bundles
as this great technological innovation.
And they are, but there's
trade offs with them.
And those trade offs are right
on the, like the quality side.
And we can do so much more than we
could, you know, even 10 or 20 years ago.
But, um, up next we've got.
A couple folks from Yuzu and we're gonna
be talking about alternative plan design.
They just raised a $35 million
round, and the yuzu story is, I
think, a really fascinating one.
So I'm really excited
to chat with the guys.
There's also a Minnesota
connection, which we love to see.
Um, let's go.
On this, on this podcast.
But yeah, I think that as we are
thinking about, you know, I talked to
the folks from Sidecar last week, it's
like this question of how do employers
save money on what is increasingly
a larger and larger line item of
their business is a salient one.
Like, we don't really have a good, uh,
a good track record of saving money
in healthcare and it's exciting, or
will be exciting to talk to a couple
folks who are, are working on that.
So I'm gonna bring Will
and Russell out front.
Welcome guys.
Russel: Thanks for having us.
Really appreciate it.
Yeah.
Um, we we're a big fan
of Health Tech nerds.
Uh, both Will and I have been a
member of the community for years.
Uh, and I think you guys
ask great questions.
I hope we can, um, we can
tell our story and, uh, and
be valuable to your listeners.
Martin: Yeah.
So are you both from Minnesota?
Russel: Yeah, I'm a 6 1 2.
He's a 6 5 1 though.
Martin: Nice.
Russel: Ooh,
Martin: nice.
Um, I like
Kevin: it.
Martin: Yes, we um, Repp in
Minneapolis as always though.
I saw actually not actually from there,
but went to college there and it's my
favorite city in the whole entire world.
So one of the things that I find most
fascinating about Yuzu is that you
all started off as a health plan.
Can you give us a little bit of
the backstory there on what it was
like trying to build a health plan?
Russel: Yeah, absolutely.
I think it was an incredibly humbling
experience more than anything else.
Um, we, we started out basically
knowing very little about insurance.
Uh, except knowing that it was broken,
which I think is apparent to many people.
Um, and we just kinda
like kept asking why.
And I think we were inspired
by, at the time, sauna Benefits.
Uh, when, uh, me, max and Ryan,
my two other co-founders were kind
of ideating and trying to figure
out how to, how to build, uh, a
business and health insurance.
We wanted to kind of bring
what Saana had done to small
businesses in Texas to startups.
Uh, we figured out quickly that
there's like a lot of issues with
that business plan, but I think,
um, number one issue that we kind of
figured out is that, uh, like building
a health plan is just really hard.
You have to have actually
differentiated benefits.
I think a lot of people
think that it's just about.
Um, you know, figuring out how to,
uh, how to kind of use data better
or like find some quick wins.
We found that actually what, you know,
when we got on sales conversations
with companies, they, they didn't
want to hear about like how quickly
we would administer something or how
tech forward our interface could be.
I think they just wanted to know like,
what are the trade offs that like you're
making that are gonna help my employees?
Like what are the costs, et cetera.
Um, and so we figured out quickly
that like we, we had to either have
a thesis about that or we had to
kind of pivot our business model.
And so we ended up kind of in a little
bit of like a, a lurch for a while
where we didn't know exactly which
direction to go, uh, but we were inspired
by the people out there that were.
Building actually
differentiated plan designs.
And so this was kind of insight
number two, if Insight one was
that tech doesn't fix the problem,
insight two was that there are
people actually fixing the problem.
And so it took us a while to kind
of understand what was going on.
But we saw, you know, plans being built
around direct primary care and plans
being built around kind of navigated
cash payment that were starting to
actually go to these employers and,
and, and employers that were in need,
um, of, of a different health plan.
Uh, for what it's worth, tech
employers are not in need
of a different health plan.
Uh, was another insight that we had.
I think a lot of people wanna sell
the startups and that's probably
great in the software industry
'cause they're cutting edge.
But in the, in the kind of health plan
industry, the employers that are most
at need are the ones that are actually
like struggling to afford benefits.
Um, and so.
We, we were able to connect with
plans that were doing, uh, that
were selling to these employers.
And they were doing so kind of with new
ways of, of building reference-based
pricing plans, um, centering DPC,
and then kind of navigated cash pay.
Um, and so that was kind of
insight too, is like these people
exist that are making change.
And then Insight three was really that.
You know, maybe we can actually
be valuable to these, these plans.
And so what they wanted was
a completely rearchitect,
re-architected kind of claims flow.
Um, different ways of kind of like, you
know, they needed something all in one
because they couldn't afford, you know,
they weren't at a scale where they could.
You know, bring on like a dedicated
member portal or a dedicated
kind of like invoicing solution.
They, they needed us to be all in one.
Um, and then they wanted us to
just kind of build with them and
listen to them because I think
we've kind of co-invented a lot of
things together with our partners.
Um, and that wouldn't have been
possible if we, you know, didn't kind
of start out at a small scale where
we were able to really craft our
product around their business needs.
Kevin: Russell will, we're having
this conversation on the heels of you
guys announcing a $35 million round.
Uh, so clearly you guys have, have,
have figured out kind of that,
that pivot towards this model.
Uh, I'd be curious, the underlying
momentum you guys are seeing,
um, with this TPA approach y'all
are taking to the market and.
You talked a little bit about how
it's not the startup community.
Who's the, the go-to-market
strategy for a product like this?
What is the employer you're
selling to like today?
Like paint the picture for me in that
in my head of like, who is the employer,
who's the target customer, and what's
the pitch conversation like with them?
Like how does that,
how does that go today?
Will: Yeah, I can take that one.
So predominantly Kevin, so far we've sold,
uh, sold to alternative health plans.
So it's like there's this growing kind
of like market movement around plans
who have found kind of the insight
that we found early on, which is like
the self-funded renaissance and like
self-funding is unbundling, right?
But then they're bundling back in.
Basically going to market,
competing with like BUCA carriers,
um, as a bundled approach.
And so like those are the
people that we actually sell to.
So like we go in as the newfound
payer platform plus TPA services.
So it's like those two components.
And we basically power those
alternative health plans.
Those alternative health
plans tend to be regional.
Um, some are national.
Um, but they, to Russell's
point are typically in the small
medium sized business market.
And like their employers who
are like hurting and like are
basically like enough is enough.
Like they're the CFOs who are
actually like digging in right?
And being like, what can we do here?
And are open to actually
crafting like these new types of
innovation within their plans.
And so that's like typically the
market of like the end employer user
skewing blue collar a little bit.
Um, typically hyper-local, some national.
But they're the ones who are looking
for these alternative health plans
and it's like really led to like
the blossoming kind of growth within
this alternative health plan market,
which like we are there to power.
Does that make sense?
Martin: Yes, for sure.
Yeah.
And let's go ahead.
Can you kind of give us some, some
sort of vignettes and like what these
plan designers theory of the cases?
Will: Oh, totally.
I'll just give you like, okay, so
almost always these employers or
these plans are winning on price.
So like it like just to beat kind of
the buca care and everything, it's like
almost always people are building or like
winning on price on, we like enable like
different kinds of types of innovation
to come to life for them to win on price.
Um, in terms of how they do that, like
it's been actually really unique to see
across the programs that we like power.
Some are really tapping into like
underwriting innovations, right?
And like bringing kind of like the
self-funded level funded down market.
Others are like ta tapping into
like cost of care innovation.
So like enabling kind of like more
direct payment, cash payment, capitated
primary care that Russell talked about.
Others are actually innovating on like
clinical innovation and like bringing kind
of like a Kaiser esque closed loop system.
Very handheld, kind of like
experiences, um, to these employers.
The, my favorite story, my favorite like
vignette is this employer group, a couple
thousand employees across multiple states.
They had rolled from a fully insured
carrier to a self-funded carrier about
six years ago, and then rolled into
an RBP plan like three years ago.
Saved a bunch of money.
Members were not getting better care.
Right.
They had the rub of like RBP
access balance billing issues.
So they come to us and they're like,
Hey, we've got this crazy idea.
We want to pair people throughout
these 13 locations in South Carolina
and Texas to dedicated direct
primary care physicians and give
them unlimited primary care access.
And so like we built the product to enable
that sub assignment of members, right?
And then they're like even crazier
when that person basically wants
to go into their like specialty
care arena when it's necessary.
We wanna pay at the point of service.
And so then we built basically yuzu
cash pay, which allows pre adjudication
onto a cash card to pay these
independents at the point of service.
And so like one fourth of people
throughout eligible employees jumped
onto this plan and won 1 20, 25 and
like 80 to 90% of medical claims last
year were pre adjudicated cash payments.
And it's like, awesome.
And so like members were
super pumped, right?
$0 care for them if they filed
guidance and the employer basically
saved more than the RBP plan.
And like the, the best part is this,
basically like the person who was doing
the care coordination is named Brenda.
She's awesome.
She's like so awesome.
And um, upon open enrollment this year,
there was literally employees across the
country who were saying, I love Brenda.
I want the bread plan.
And enrollment doubled
there, like doubled.
It's awesome.
Like, and like who's talking about that?
Like in their health insurance, you know?
And it's super cool that that's
what makes like Russell and I proud.
Martin: That's really cool.
Kevin: Yeah.
The
Martin: brand of plan.
Kevin: I, I, I'd be curious guy.
So we were just talking with Neil Shaw
about the change in maternity space and
how, how that payment model is changing
from bundled to unbundled and how that
might drive increased costs for employers.
I, I'd be interested to use that
as an example of kind of the change
of foot in the employer market.
How do you, are you guys proactively
keeping an eye on stuff like that
and surfacing that and, and designing
kinda, here are the options of maternity
care that y'all should be looking at.
Are you letting employers
sift through that themselves
and come to you guys, or how.
How does change like that flow
through with, with your plan offering?
Russel: Yeah, that it's
a, it's a good question.
Uh, first of all, I'll say that we support
probably about 10 plans, and they each
have like different ways of doing this.
Uh, some of them on the more basic
side are just Cigna plans, and they
pretty much, you know, they've got an
underwriting and a distribution strategy.
But in terms of like how people
get care, it's pretty much just the
Cigna pre-certification process.
Um, the more innovative plans
though, our take is that the
best ideas come bottoms up.
And so actually we're not, we don't really
believe that sign sort of like our, yeah,
we're, we're pretty far away from the, the
member and, and, and the care coordinators
that might be within these health plans.
And we believe our job is to pretty
much enable them to be creative and
to have the tools that they need to
access the right trade-offs for members.
And so.
Although we, we do have products that like
notify care coordinators, um, who exist at
our health plan customers about, like pre
certifications, about eligibility checks.
Um, we, we kind of have an integrated
communication model so that care
coordinators can see every time someone
got a welcome email or an EOB or
whatever and see the claims in real time.
But in terms of like ideas for doing
care coordination, those come bottoms up.
And I think that that's kind of
the, the, the, the way we see
ourselves is we see ourselves as
a vendor of these health plans
instead of them being a vendor of us.
Um, as like care coordination vendors.
Like we, we see ourselves as like
administration vendors of them because
this idea of like, how are we going
to communicate, you know, care options
to people, that is the hard part.
A hundred percent.
And we've seen some like ridiculously
creative things that have gone on
because there was a high level of trust
between those care coordinators and.
Patients and employers.
And so we've seen, you know,
waived everything to go to a
surgery center out of state.
We've seen, you know, people
kind of actually like lining up
colonoscopies back to back, to back,
to back, to save on anesthesia.
Uh, we've seen like weird
stuff that we could never have
actually coordinated ourselves.
And even if we did coordinate, it
wouldn't have come from like that
position of trust and that position
of caring for a member and really like
knowing what's gonna work best for them.
And so I think our take is that even
though health plans think they have all
this data, um, there's only so much that
ICD like that H picks codes can encode.
And you really want to
be able to utilize the.
Kind of contextual information that,
that, that exists on a more local level.
Um, and and to do that, you want to
almost figure out how you can trust
and incentive align with people that
already have that information, whether
it's the referring doctor, whether
it's a care coordinator, whether it's
the employer or the member themselves.
And so that's kind of like our, our
take is to wrap around them and try
to make sure if we trust 'em, we
want that person to be super powerful
within the plan, um, and have kind of
the ability to waive certification if
necessary and all this other stuff.
And so we have to record those events
and make sure that they're visible
to stop loss carriers and other
partners, um, kind of our model.
But, but we want the kind of right
decision, whoever has that right decision
to be able to make that right decision.
And it's not always, and not even
usually us, on those creative
kind of care navigation events.
Martin: There's clearly a lot of interest
and demand for alternatives to the current
system, especially at the employer level.
Right?
Costs are going up every year.
It's unpredictable.
It's just like a bad, a bad situation.
I sit in Washington, DC and
most of the attention it feels
like from my perspective in
Washington, DC is about IRAs.
I'm curious for the house view on,
uh, uh, from yuzu on IRAs and what
policymakers should actually be focused
on, um, if it's not this, this icra.
Russel: Yeah.
I will say, I've got a blog
post on yuzu.health/blog
about this if you want.
I did
Martin: a, I did.
That was a, a tee up for, because
Russel: Yeah.
Yeah.
Uh, I, I would say Icra is not solving
the fundamental problem of just how
do you balance things within the plan.
The most inefficient parts of a
health plan are really like network
access, pre-certification kind of
payments, taking a long time and being
difficult to understand and organize.
And, and those, those, those
things are not solved by Acra.
And so Acra does kind of give members
some choice over how to spend dollars,
and I do appreciate that it's bringing
employers kind of more, you know,
like another topic to think about
as they kind of craft benefits.
But I don't think it solves the
fundamental kind of challenge of kind
of network access, pre-certification,
kind of what's covered, what trade offs
are being made at like the group level.
Um, and so I think like we, we kind
of early on considered being an icra
platform and decided it just didn't
go deep enough for us, uh, and that
we wanted to go a level deeper.
And I think it's kind of like concerning
that the incumbents in insurance
are not scared of icra at all.
You know, they're the ones
that are lobbying for it.
Um, and so I, I see it as an
extension of the status quo.
But that said, I think there's been some
players in the space that have gotten
good distribution and brought attention
to the right issues and they, they
might be able to kind of launch their
own plans on some of that distribution
and, um, trust that they've built.
Martin: I think we're at time and so if
folks wanna get in touch and learn more,
besides reading the really great IRA post
that Russell did, uh, on the UV blog,
and if I do say so myself, a fantastic
interview with, uh, Russell that we Health
Tech Nerds did a couple months back.
How can folks get in touch?
How can folks learn more about Yuzu?
If you're a creative plan designer
who's got, um, a, a theory of the case
for how to make things better, what's
the best way for them to get in touch?
Will: Yeah.
Um, my email's will@uzu.health,
Russell's, it's russell@uzu.health,
um, or trickle into our website.
There's a bunch of good
content in the blog.
It like, well depicts who
we are and how we work.
Um, so I'd also point
you in that direction.
And like, before we wrap too, I
just wanna say thanks to you guys.
Like both Russell and I are Minnesotans.
We've been a part of the
community for a long time.
Like, I remember before I joined over
three years ago, I would see Russell
posting just outrageous questions in
the health tech nerd Slack channel.
And like, people were like keen to
respond to him, you know, like they
jumped in and, uh, Russell has a good
blog, uh, called asking dumb questions.
And like people were welcoming of that,
you know, and like taught us a lot.
And your community has fostered that.
So we're thankful for you.
Kevin: That's really nice.
We love it.
Yes.
Thanks guys.
Well thanks for joining guys.
Appreciate you.
Always fun talking to other Minnesotans.
Martin: Amen.
I think that the alternative plan design
space is like one of the more interesting
conversations that's happening and
seeing, like hearing, like, like lining
up back to back colonoscopies, like the,
the CRE to save on anesthesiology is
like one of those things where you're
like, yeah, that's not, I think it's
basically impossible to do at scale.
And if your employer comes to you, like
Kevin, if you came to me and said like,
we're, we're, it's, it's colonoscopy
day at Health Tech Nerds and we're all
taking a field trip to, I'd be like a
little bit skeptical, but I think it's
just, I don't know, I just think it's
like fascinating that you can kind
of pull these sorts of things off.
Kevin: Yeah.
It reminds me a little bit of the convo
I had with Tom Freeman from the North
Carolina State Health plan the other day
about some of the things they're thinking
about in terms of managing costs and like
it actually, if you are, if, if you are a
forward thinking employer and you've got.
The support and mandate to
go do some creative things.
I think to the, what use you
just raised, you can do that.
I mean, ultimately you're the one
paying out, um, the healthcare dollar.
And so it's a, it's a really interesting
role to be running benefits for
organizations like that and thinking about
what can you do to get creative, right?
There are all the news stories
about can you send people to
different countries to get their
medications 'cause they're cheaper
and you can pay for the whole stay.
And Tom Freeman mentioned you could pay
for a, a limo and hotel stay to get people
at the right spot, um, for surgeries.
There's all sorts of wild different
stuff that you can concoct if you're,
uh, if you're in one of those roles.
But it is fun.
I, I think, I mean, given cost
increases that employers are facing,
I we're clearly gonna be talking about
models like this a lot more, right?
And to me it's just, I have these
questions in my mind of large
group versus small group, how that
changes, how those are potentially
different and or not different.
Um, the CRA conversation is
certainly an interesting one.
I know there are a lot of opinions in the
industry on where CRA is heading, um, how
that materializes for small groups, but
orgs like yuzu have a real opportunity
to help drive some of those, um, new
different plan designs, particularly
for forward thinking employers, right?
Martin: It's a lot.
There's, you know, speaking of ICRA
and the A CA marketplace, there's been
some news this week on the subject, you
pointed out in the newsletter that Baylor
Scott and White Health Plan is exiting
the a CA market and their Medicaid plan.
Yeah.
What's going on over there?
Kevin: I saw that article come up.
I don't know that there was, I was
looking for details on, you know,
backstory, the why, et cetera.
I, I didn't find much beyond
their, their exiting the markets.
Um, I think
Martin: you and I both, I have theory.
Kevin: Yes.
I think we both have a theories.
Let me hear yours.
Martin: Well, it's a really bad time
to be an a CA plan and there's a lot of
tumult and uncertainty and it's also, is
Kevin: it a good time
to be a Medicaid plan?
Martin: Oh, it's a way
worse, just way, way worse.
So, yeah.
Off the top of my head,
that's sort of what I expect.
And then,
Kevin: and Martin, when Mark Cuban
Cost Plus Wellness is just sitting
there in your market, why do you
need an insurance arm to begin with?
You should just be the low cost hospital
provider in your market and contract
directly with employers because you can
just get rid of all the inefficiency
that exists in the ecosystem.
Martin: Yeah.
You can just, that money was not well
spent and smart people haven't been
trying to do this for a long time.
Uh, we, Oregon also placed a plan
under receivership, which Yikes.
Um, yeah, I think the plan was called Ario
Kevin: Atrial.
Yep.
I had not heard of atrial before,
personally, but yeah, I mean, it's
another example of a plan that, um.
I think it had 36,000 Medicare
Advantage members, so not a small
plan, but it lost 50 million in 2025.
It only had 10 million
in capital and surplus.
I think I was reading that
they potentially had some uncla
unpaid claims to providers
that they were being sued over.
In addition to that,
Shiv: yeah.
Kevin: Put this under the broad theme.
We've talked about repeatedly about
the challenges facing regional health
plans today between this and the Baylor
Scott and White Health plan example.
I just, it, it's, it is a tough time,
I think, to convince me that it is,
you know, good as a single state
provider sponsored health plan and or
just regional health plan in general.
I, I think it's a sign of the times.
Martin: Wakely released their first,
it was basically the first data point
we got on effectuated enrollment.
It's not the official effectuated
enrollment in the a CA marketplaces, but
this is their sort of back of the envelope
math based on January premiums paid.
And, um, and a couple other things,
they're saying it's looking like
January paid premiums were about 85.9%
of the total enrollment.
So it'd be a, you know, roughly
14% loss from the numbers that CMS
published in the beginning of the year.
That is less than some
plans we're expecting.
Now that's a national number and
so you don't read too much into
that and say, okay, these plans
are saved, these plans are screwed.
But in general, I think that the
sort of golden path for plans this
year was, um, enrollment being low
and them sort of benefiting from.
Or, sorry, excuse me.
Uh, enrollment being higher
than expected and it seems like
that's maybe going to happen.
Kevin: Yep.
It's, it's in, so Wakely, I think
in the report, said that they're
expecting on the whole enrollment
decline speed between 17% and 25%.
So back to your point in my head, this
is, and this I get a little confused
on in the a CA, but you can, so this
report was people who had coverage
in Jan but didn't pay in January.
But they have a grace period
that's longer than that.
And so Wakely is saying over the next
couple months in total, it's gonna go
from 14% up to, in that 17 to 26% range.
Martin: You know, that's what I thought.
Patrick: Go ahead.
Martin: But it's actually,
is that not right?
I think what they're saying
is at the end of the year.
What enrollment's gonna look like.
So there's always a lot more turn.
Yeah.
So that was my, I was like, oh wow.
So the, the grace period for the
aca, if you have a subsidized
premium, you get 90 days.
But if you have subsidized premium, it's,
I think that number will likely go down.
Right?
It'll probably actually be less than 85.9.
But the universe of people who are,
have subsidized premiums and don't
pay their premiums should be lower
than the total universe of people.
You know, I'm gonna actually pull up a
slide that will help me make my point.
So Wakely included this, uh, sort
of helpful graph, which was premium
increases by paid premium percentages.
Basically the more premiums went up in
your state, the uh, the sort of higher
the, um, the more premiums went up, the
lower the percentage paid of premiums
is if you have a subsidized plan.
I mean, yeah, like this
is pretty intuitive.
Interesting.
If you have subsidized rates, you're,
you're probably going to use that subsidy.
Um, but not a hundred percent.
So eight, I think 14% is like a pretty
good mark for effectuated enrollment.
We'll see though, 'cause
CMS hasn't released it yet.
The, the grace period kind of just ended.
Kevin: Yep.
Martin: Recently.
Kevin: What's your take on, um,
Wakely also seemed to indicate that
the, uh, the morbidity in the market
was going up, what, two to 6%?
What was your take on the morbidity
numbers and what that means for plans?
Martin: So this was expected, right?
The, the a CA original design was saying
everyone has to have insurance and that's
how we're going to solve this problem
where we have adverse selection and then
we got rid of the individual mandate.
'cause people didn't like it.
And now the way that we kind of handle,
um, the adverse selection problem is
by pumping more money into the system
by giving more generous subsidies.
So we knew that if the subsidies
expired, things were gonna get, that
the risk pool was gonna get sicker.
It makes sense.
If you don't think that you need
insurance, you're not gonna buy
it 'cause you don't have to.
Um, and so we knew it was gonna go up.
I think the question is that those
are pretty wide error bars, like 2.9
to six point a half percent morbidity
shift is, is pretty significant.
And it, it feels like, again, the
happy path is a lower morbidity,
lower uh, attrition than expected and
then lower morbidity than expected.
And so as we tune into earnings calls
starting, um, over the next couple, you
know, couple weeks, like this is gonna be
what's gonna be interesting to talk about.
Kevin: Yeah, for sure.
I, um.
As we wait for Shiv to hop on
here, we can keep talking about
this for a couple more minutes.
Um, I, one of the interesting things I
recall hearing, I, I forget if it was
an earnings call or log post or whatnot,
but it was talking about the fact that
this may actually play into 2027 as well.
Um, which I back to one of our other
general themes of uncertainty in markets.
Like it's, it's gonna be interesting to
see how quickly we can clarify what's
going on here, what that implies for
folks, actuaries and these plans who
need to underwrite these policies.
'cause those decisions are
coming up pretty quick for 2027.
Martin: Yeah, there, we also haven't
gotten the final rule for 2027.
Um.
The 2027 a c, a plan market.
So the administration had all of these
kind of thoughtful, creative ideas
on, on ways to switch up the market.
Longer term plan designs, like
two year plans that you sign up
for expansion of catastrophic.
The big one that got a lot of
press was the no network plan.
People are very upset about this
and that final rule is pending,
but has not come out yet.
And so if you are, I mean, it's
just been a, like I know that no
one is ever inclined to feel sorry
for insurance plans, but man, like
what a rough time to be an insurance
plan in the a CA market like.
We don't know what the final rule is
and exactly what the, the rules and
regs are gonna be for 20, 27 states are
starting to collect that information.
You had a fire drill last year where
you submitted two sets of rates.
You did the lower rates, um,
based on, you know, maybe people,
maybe the enhanced subsidies will
get extended, maybe they won't.
And it went right through the
end of the year where it was a
sort of, will they, won't they?
And man, I don't know.
It seems, I don't know.
It seems like a tough time to be an
insurance plan in the a CA marketplace,
which might be why Baylor Scott and
White was like, oh no thank you.
Kevin: Yeah.
Do you, do you remember Aetna, you know,
this is now months ago, decided to exit
the a CA marketplaces and there was this,
a similar conversation that felt like that
we had at that point in time of like, I.
There's so much uncertainty that,
you know, maybe you're leaving some
opportunity on the table as the
market calms down in the, uh, you
know, uh, in the coming years, but
in this period of uncertainty, like
why, why participate if you're a plan?
I, I don't know.
Martin: Well, in the community this
morning there was a discussion, shout
out to, to Lisa Barry, who, who posted
about it, but Nevada is launching a state.
Public option basically.
And normally when you hear public option,
you think, okay, this is a plan that's
run by the state, competing with the
insurance companies and acting as, you
know, a sort of self-regulating mechanism.
Like one of the things that market
oriented public option proponents really
like is they say, okay, here's a really
cool, there's this really great way
where we can not do a ton of regulation.
We've got shiv, I'm
gonna bring 'em forward.
Um, and then we'll go back to talking
about public options in a little bit.
Shiv, welcome to the show.
Shiv: Hey, thank you so much.
Sorry I'm late.
Add some technical.
Martin: No, no worries at all.
Uh, how are you doing today?
Shiv: I'm doing great.
Yeah.
Happy Monday to you guys.
Yeah,
Martin: happy Monday to you.
I.
Actually, I'm gonna kick it over to
Kevin, 'cause he was actually at JPM
and, and has some, some thoughts on,
Kevin: I love listening to
your JPM presentation, as
always hearing you talk shiv.
One of the, um, one of the, the, the
framework that I left that presentation
with and then saw again in your guys, um,
news about the partnerships with jama New
England Journal of Medicine was this idea
of the pre-visit conversation during visit
conversation, post-visit conversation.
It seems like the, the partnerships
y'all announced were, are, are focused on
the during visit conversation, clinical
decision support as part of that.
But I'd be curious if you could give
us the lay of the land of how you
think about the product offering today.
Expand on that pre, during post, and how
this content partnership fits into that.
Shiv: Absolutely appreciate that.
Um, so high level, the mantra inside
of the company, inside of a bridge
is that we wanna aspirationally,
we wanna save time, we wanna save
money, and we wanna save lives.
And as a cardiologist saving
lives, we take that very seriously.
It's aspirational.
To be able to demonstrate
that takes, takes time.
But you gotta start somewhere.
You gotta start with product.
And when we think about product and the
product, user experience, chassis, if you
will, we think about what happens before
I walk in the room to see my patient.
What happens during that moment
when I'm with that patient?
Then what happens after all the work
that happens afterwards in terms of
looking things up or creating artifacts
that I'm entering into any number of
different systems of record, for example.
But before the conversation, I
might be prepping for that patient.
I'm about, I'm about to see, I used to
have a, a Monday morning clinic, uh,
a cardiology clinic and every Sunday
night I'd be in front of Sunday night
football just prepping my charts.
I'd be looking up all
the complicated patients.
It would bring my blood pressure down.
I'd feel a lot more at ease the next
day that I could actually do a good job.
Not only could I be timely, but I
could actually be a prepared mind
walking in the room, feel like a
little bit more of a superhero.
But with this technology, we can,
you know, put that on steroids.
Now, before I walk in the room, I
can really know who this person is.
I can even be queued on what
questions I need to ask or
what articles I should read.
And those articles
could be outta UpToDate.
We've announced that
partnership in the past.
It could be from New England
Journal of Medicine or from jama.
But I can kind of walk in that
room with a lot of the data,
a lot of the evidence sort of
contextualized to who this person is.
And then I walk in the room and our
ethos continues to be no distractions,
eye contact being present, no
beeping sounds, no flashing lights.
But when I look down or look, look to
the computer screen, I should be able
to get that cue and maybe, you know,
you should be asking these questions
or considering this differential.
And then afterwards, obviously I can
continue to query against all the context
now, not just from the record, but
also from the conversation that I had.
Hopefully that kind of
makes, makes more sense.
Kevin: Uh, I'd be curious, um, if
you wouldn't mind walking through
a specific use case of this, like
in my head I've got it as kind of.
Google search, I type in a question and
it, it, it references the literature, but
how, how does it fit into your product and
what's the, are you typing in questions?
Is it ambient as well?
What's the, how does it fit in?
Shiv: Yeah, so maybe a couple ways
I can describe how it fits in.
One is through the, the technology
at actually very politely, very
hopefully, tastefully giving you cues.
So, um.
Saw a patient recently and and Chase,
one of our clinician scientists,
will bring up this example as well.
The patient happened to have a certain
type of medical history and also had
a certain BMI and I was seeing this
patient for chest pain and the usual
course of action for chest pain in
a patient who's got a lot of risk
factors is to do some sort of risk.
Factor stratification or like a
stress test of some sort to sort
of figure out what's going on.
And I ordered a certain type of
stress test, a nuclear stress
test, but then afterwards the
technology queued me very quickly.
It didn't call me an idiot, but it
said, Hey, do you want to reconsider
the nuclear modality and think
about doing a pet like a mibi?
Um, and, uh, maybe it would be a
better, potentially a better choice.
And you wanna read more on why.
And if I hit that button, I could very
quickly, um, look at the evidence, you
know, where that's coming from, whether
it was an UpToDate article or a New
England Journal of Medicine article.
In that case, like I can actually go
down all the way to the data and build a
lot of conviction and changing my plan.
If I wanna change my plan, I can simply
free text that I can say, okay, adjust
my plan to reflect this and also adjust
my orders to reflect this, this, you
know, evidence or this data that I just.
Um, so everything's like
very deeply integrated with
our enterprise positioning.
I'd say like that's the most important
aspect of a, like all, all the product
features that we build is, is trying
to build as much trust as possible and
feed as as much context as possible.
Martin: One of the things that I find
fascinating about this space is like, it
feels like up until maybe like five years
ago or four years ago, clinical decision
support was like highly algorithmic.
It was like, okay, there's a drug drug
interaction and we can like surface that.
And what that led to, I think was
some, some alert fatigue for doctors.
They were getting kind of bombarded
with like, you got these alerts.
Um, how are you thinking about, you
know, you have, you've announced
these partners with the New England
Journal of Medicine and with jama.
How are you thinking about.
The sort of the, the right context
and, and sort of fitting those in
so that it's not detracting from
the sort of patient interaction.
Shiv: Yeah, it's, it's a great question.
I remember those clinical
decision support as a term too.
It doesn't feel as cool anymore.
It feels like clinical intelligence
is the new way to describe this space.
Um, I used to be a corporate
VC of sorts at a large health
system at UPMC years ago, and we
invested in multiple CDS companies.
And at the time, you're right, it
was basically best practice alerts.
It was alert fatigue, it was popups.
And like, the best you could do is give
a surface, a popup at the right time, you
know, at the right moment in a workflow.
And, um, try to introduce
friction that a clinician might
hopefully perceive as good.
Um, but this is a new moment where,
especially when you think about.
Products from like an AI first, from
an agent first sort of standpoint.
There's so much work that you can do
in the background and there's context
that you can kind of engineer the new
term as obviously not just context
engineering, but harness engineering and,
um, and, and how can you, how can you
kind of safely, um, lead the clinician
to the, to the right data to help?
Augment their decision making, improve it.
So to, to do this in a way that
really works, um, for us evals,
um, have looked multifold.
Like one is just quality.
We score all of our outputs against
a physician built rubric system.
Another is just testing for adversarial
use because I think you're speaking
to, or we're speaking to the user
experience where it's, it's, it can feel
pretty open-ended and so jailbreaking
can be, um, a risk and that you need
to build the right guardrails into
that harness to protect against that.
And then another is just like straight
safety from the standpoint of surfacing
the wrong research papers or the,
like, the wrong drugs or, or, or
missing key parts of the context that
you're feeding in, in the background.
But we've now used, you know, uh, well
over a thousand really, really deep.
Test cases to build rubrics developed
by clinicians that kind of got
us to this point of conviction
that this is ready to go ga.
Um, and that's what we, what, what we
just announced, but it's a treadmill,
like we'll always be running on it,
just the way we run on all things
related to like mid revenue cycle
and clinical documentation for that.
Kevin: As an aside, as a MBA intern at
Medtronic in 2010, I remember putting
together a slide deck on clinical
decision support and alert fatigue and
how hot of a market it was at the time.
But just on this intellectual level,
the idea of Medtronic getting involved
in clinical decision support, I think
played into some of that alert fatigue.
And when you think about the
underlying incentives there,
I'll leave that aside for now.
I, I'd be curious if to, to go back
to, um, JP Morgan presentation.
You talked about, I think a
bridge is live in something like
200 plus health systems today.
Uh, a lot of providers are using it.
It's used in a lot of
patient conversations.
I'd be curious to hear you reflect
on state of play from a go to market
perspective as an AI solution.
Obviously we have seen, uh, an explosion
of health system interests and these sorts
of tools over the past several years.
It strikes me that.
If I'm a health system leader,
I've probably thought about this
question, have put in place the rails
of what my AI deployment strategy
is within the system at this point.
Shiv: Yeah.
Kevin: How do you think about
conversations with existing systems, with
potential customers about feature set?
How you're building that out,
how something like this fits in?
Shiv: Yeah, it's, it's go to market is
everything, especially in healthcare.
Um, and you know, like people think
that healthcare is one homogenous
market and obviously it's not.
And it's, we think it's really difficult
to swim upstream, but it's way more
possible feasible to go sort of, sort
of go downstream from like those big
systems from, from the IDNs and the IDFs
and the payer providers and the AMCs.
So we, we yoed it.
You know, in 20 22, 20 23, and went
to the big systems, and now over time
we'll start to expand and extend.
But within those big systems, the, the,
the barrier for good enough, um, against
even the first use case, like still
high, like, uh, by that I mean like the
threshold for good enough because they
need a solution to work in an enterprise
grade way per the CIO that can help
all their clinicians and all their
specialties and all their spoken languages
and all their different care settings.
But then, you know what, what we
quickly discovered is that there's so
much more that you can extend into,
whether it's move upstream into what
happens before that encounter or
downstream into what happens after.
And like as an example, like,
uh, you, we might sit with a
sit down with the CIO who's.
Thinking about, you know, an ambient
solution, but they're also separately,
maybe a couple years ago they were
thinking about a CDI solution, and
then you need, you sit down with them
and you help them understand, actually
behind the scenes we can shift left on
a lot of that CDI work and get it done,
um, even before the node is generated.
And now you don't need to worry as
much about CDI solutions for XY, Z sort
of, you know, um, you know, VA value.
And it's an epiphany for them.
And, and so it's the same
story for prior authorization.
There are a lot of health systems who
are, you know, were experimenting and
especially a couple years ago with prior
auth, uh, solutions that might live
like downstream and they're aggregating
data across a lot of different systems
and trying to help make the process.
For my backend administrators, a little
bit more simple, helping them kind
of get into those payer portals and
upload all the PDFs or, or fax data,
you know, in a more efficient way.
And then we would try to help them
understand, well, actually what happens
if you just sort of shift left again
and have these agents and subagent
understand not just the context of
who this patient is retrospectively,
but here are the conversation.
Cue the clinician on gaps, they
should close, and then create all
the right documentation and send
it automatically to those portals.
And even in, in the case of a couple
different payers, actually round
trip the authorization in real time.
And it, it, it starts to, it helps
them sort of understand that actually,
like you, you can kind of collapse a
lot of care delivery work workflows.
Um, if you start to, um, you know.
Just challenge your priors on, on, you
know, what it could look like if you
redesigned the entire system from scratch.
Um, and I think that's really the
opportunity with AI is to just
like, think, think about, you know,
uh, collapsing and compressing
workflows as much as possible.
Martin: We, I know we're, we're
getting close to time here, so last
question for you is, one of the things
we think about a lot here is like,
okay, where are we gonna start to
see the impact of AI in healthcare?
I think, you know, there's some people
who say, we're starting to see it
in coding, maybe in sort of ambient
scribing and, and productivity.
There are other people who are
skeptical and they say, this is a
silos paradox thing where you can see
it everywhere except for, you know,
the consolidated financial statements.
From your perspective, where do
you think we, we start to see the,
the impacts of AI in healthcare?
Like, what are the things that you're
most excited about and where should
we be looking for those screen shoots?
Shiv: Yeah, I, I have been
thinking about this quote a lot.
Like there's a Bezos quote from years
ago that when the anecdotes and the
data disagree, believe the anecdotes,
and that was very much like the story
for us in like early days of scaling.
We're now live in well over 270 large
health systems on a run rate to be a
part of well over a hundred million
encounters in the next 12 months.
And hopeful a lot more
than that, um, this year.
And.
Early days though, before we got to that
scale, we'd have doctors tell us that
for the first time they're experiencing
Los Angeles rush hour traffic.
Um, and that felt like real,
that, that felt like data that
felt like, you know, a big win.
But then we would go to that same system
and that same users sort of like data
from existing telemetry systems and there
was no indication that they had saved any
time and we're like, what is going on?
And so over time, and it's still like
a moving target, we've realized that
a lot of different systems in in are
instrumented in different ways and
it's, it can be pretty difficult.
So you try to find all the
proxies you can for the value
that you're trying to create.
Um, save time, save money, save lives.
I think that money piece is so important
to us because like, it's one thing to
deploy an AI system and deploy it into
the existing system without thinking
about compressing and collapsing
workflows and creating those efficiencies
impacting not just the bottom line,
but also figuring out how you can, you
can find positive some sort of models.
Between all the rate that the stakeholders
in healthcare and thinking about
payers and providers specifically.
But that has to be the goal, um, in, in
our estimation, because otherwise we're
just gonna be deploying, obviously, like
agents on top of existing workflows.
And that bal cost disease curve is gonna
look even steeper than it already does.
So for, for us, it's, it's a finite
number of use cases that we're
putting a lot of energy into that
can demonstrate that win-win, where
we're threading the needle through
the most important people, patients,
and their care teams, those end users,
but also those existing stakeholders.
Prior auth is a really
good example of that.
But, um, certainly a lot of the work that
we're doing, um, like the announcement
that we had with Availity, for example,
at JP Morgan too is, is all about that.
Martin: Shiv, this has
been hugely helpful.
Thanks so much.
If folks wanna learn more about a bridge
though, I, I think everyone listening
has probably already heard of a bridge.
Where is the best place on the
internet for them to do that?
Shiv: Yeah, well we have to, we'll do a
better and better, like, we'll do a better
job of putting a lot more information
on the website, but that's a good spot.
Um, LinkedIn is, I feel like, where
you have to live as an enterprise
healthcare company, and so probably
our LinkedIn account is dropping as
much information as anything else.
Martin: Great.
Thanks so much for your time today.
Shiv: Awesome.
Thanks for joining
Kevin: us.
Shiv: Yeah.
I really appreciate it.
Thank you.
Martin: It continues to be, you know,
as we gear up for our earning season,
I continue to be fascinated on where
we're gonna start to hear and see
these, these efficiency improvements or
productivity improvements for, for ai.
Kevin: Yeah, I, I, I shivs point
about when the, when the data and
the anecdotes disagree, believe the
anecdotes, I think is an interesting one.
Um, and good one, and I, you know, his,
he made the same point, the story about
the provider seeing rush hour traffic
in la He made that point at JP Morgan.
I think it's a really salient example of
like, for the first time, these providers
are going home at a reasonable hour,
so they see rush hour traffic, right?
Like yeah, it's a, it's a good
point he makes there, and it's a
compelling story to your point on
earnings calls, the anecdotes fall
flat compared to that one, right?
And so, yes, like I, it'll be interesting
to see where those anecdotes are that
are actually finding meaningful progress.
Martin: I'll also say, you know, I spent
some time with BLS wage data for, for
doctors, and one of the things, you know,
depending on what deflator use, it's like
maybe has not kept up with inflation and
PCPs are getting paid a little bit less.
They were 10 or 15 or 20 years ago, or has
kept pace with, you know, CPI inflation.
So a doctor's getting
paid roughly the same.
Mm-hmm.
And when you talk to doctors, one
of the things you hear is like,
they, they feel busier than ever.
And so a something that allowed
them to sort of tread water and,
and stay in the same place would be
actually an amazing technology, right.
If you're not getting paid more in real
dollars, but you also get to go home and
see your kids at the end of the night.
Like that seems like a, maybe a
reasonable, a reasonable trade off.
Kevin: Totally agree.
Martin: Next up, we're talking about
access, and so I'm curious if you
have any, uh, we, we have Patrick from
Withings, a French company, though
he's working on the American business.
Um, I'm curious if you have any thoughts
on, uh, any further thoughts on access?
Like what is, as you are
thinking about the program, what.
What continued to be the
open questions in your mind?
Kevin: Yeah, I, so going back, 'cause it's
been an hour and a half now, um, since
we talked about it last, uh, so program
announced participants on Monday, right?
Withings is one of 'em.
Um, it was fascinating to me to
see Withings and whoop participate
as kind of non-traditional
healthcare participants, right?
Organizations that are
certainly in the ecosystem.
I have been a Withings customer
for years now with their skills,
blood pressure cuffs, et cetera.
Like it is one of those products that I
think just works and works really well.
So excited.
I have Patrick on here in a minute
to talk about how they're seeing the
world, but I, I think it is interesting
to see the participation there from
those two companies in particular and
think about what that implies for the
access model and how if the theory
of the case coming outta CMMI is.
We need to use AI to bend the cost curve.
We want to target kind of the,
the lower risk Medicare population
and potentially use that to work
our way up and expand over time.
I actually think that's a really
logical theory of the case, that
this would be a good place to start.
Right.
Um, and so I'm, I'm, I'm curious, like,
to me that's kind of the, the thought
exercise that I'll probably be thinking
about as we watch access roll out over
the coming months is like, can you,
can you rethink it from that direction?
Because obviously we saw in the, in
the announcement on Monday, digital
health doesn't, in general, doesn't
seem to think that you can rethink
it, um, when you are coming from
kind of the traditional lens, right.
Martin: Yeah, tech enabled services is one
of those things that, you know, comes in
and out of popularity and it feels to me
like CMS is saying we want, uh, we want
it to be, we wanna really underscore and
underline the tech side of it, which is
what makes the winnings and, um, and or,
uh, participation So fascinating to me.
I think a lot about or is
Kevin: not in it, I
think you meant, whoop,
Martin: I did mean whoop
Kevin: ora did not participate,
which is also interesting, but
probably a different conversation.
Martin: Um, yeah, and so I, I think that
when I think about behavior change, I
think behavior change is really hard.
And I think that one of the things that
you sort of need for behavior change to
work is some sort of realtime feedback.
And so it, the more I think about
it, the more it makes sense to me
that a, a connected device company
would be able to better provide that
realtime feedback than something that
is purely digital health focused.
Kevin: Totally agree.
Martin: Alright, I am
gonna bring Patrick on up.
Hey Patrick, how are you?
Alright.
Patrick: And Kevin, great to see you guys.
Kevin: Good to see you.
Patrick, welcome to the show.
Patrick: Thank
Kevin: you.
As you probably, as you probably heard
us just teeing up, we're excited to
talk with you about, um, what y'all
up to it Withings, uh, the access
model in particular, how you're
thinking about the opportunity there.
So maybe let's start with that.
I'd be curious as one of the, the
hundred 50th, 50 ish participants
in the model, how are you
thinking about the opportunity?
What gets you excited about the model?
What led you guys to apply?
Patrick: You know, I, um, one,
we're very excited and thank you
Martin and Kevin, uh, for having
us on and talking about access.
Um, look, I think access is like a
big moment for digital health and
you guys spoke about it very well.
Like, why hasn't digital
health come more to the table?
Maybe like the role of the device is
like really important here, but the
more that we got into the weeds of
access, the more we spoke with Jacob
and company at CMMI, the more we were
like, actually this is a great model
for a device company and all of our
exper expertise and delivering care and
enabling care and the Medicare population.
Um, and you know, what we think about it
is, look, the hardest part in all of this
is getting a patient to use a device.
You know, I think a lot about, like
the payment is fully contingent
on a patient using a device for
the baselining, for the quarterly
payment for the end of year payment.
The device is core to all of this.
And, um, and we also know that patients
love using our devices and that blend of
like, consumer plus we have huge amount
of healthcare partnerships with ACOs,
health systems, getting data back to PCPs.
I could talk endlessly about it,
but we felt more and more that the
people who were gonna succeed in this
model or those who have that consumer
backbone, but also have the right
pipes into the healthcare system to
have that coordinated collaborative
care approach for the patient.
Martin: The main thing we've heard
from folks who are not participating
is some complaints about the rates.
Obviously, we're not looking for you
to get into your secret sauce here.
Yeah.
On, on how you did the math, but
curious for your high level reflections
on how you interpreted the rates,
what you're sort of seeing as the
opportunity here and how you're
thinking about, you know, leveraging
AI to help make this stuff work.
Patrick: Yeah, so the rates as they are
today are sustainable for Withings, but
Withings we're kind of, and other device
companies were kind of unique because we
own the main cost structure and this care,
which is the hardware required, uh, to
be able to manage the patient remotely.
You know, the way I think about it,
and you guys probably think about
it the same way, but this is a
pilot and you know, we're coming in
the first year, the first cohort.
I think a safe bet is that this is going
to evolve as time goes along as well.
So like, as the rates are today,
we're very happy with them.
Uh, we're looking at a sustainable
business in access alone, but we're
also really thinking about, hey, this
is the star of a pilot with CMMI.
This is going to evolve quite rapidly.
You know, I, you know, we were
talking about, um, we we're all
rooting for this as taxpayers, right?
For this to succeed.
You guys were opening up with that
today, I think about MSSP, you
know, like in 2014, you know, PCPs
were saying, we can't do this.
Like, this is too low of a rate.
We're not gonna, it's not gonna work out.
And you fast forward a little bit and
you had these insurgent models, right?
You had these enablers pop up because
they had the core technology of
like pop health analytics, really
robust to enable that payment,
enable success in the MSSP program.
I think access is kind of the same way
where the incumbents, you know, this
is difficult in the status quo, but
we're gonna have this insurgency of.
Companies who have the right technology
in place, who can build for it.
Um, and I think this will be
a very successful program with
the right people at the table.
Kevin: Patrick, I think most of
us think of Withings as connected
device company, manufacturer
scales and blood pressure cuffs.
Uh, people use them in their
homes to be part of this program.
I'd be curious, are you
expanding scope of Withings?
Like there's been conversations about
becoming Medicare provider, part B
provider to participate in the program.
What have you had to build on top of kind
of the core connected device offering
for access in particular and how you're
thinking about that moving forward?
Patrick: Yeah, so we are a
Medicare Part B provider today.
I think of it as, you know, one, it's a
natural evolution of what we do every day.
So with thing is, I mean, we have
15 million users around the world.
Kevin, I know you're,
you're one of them as well.
We have a medic, a million medical
patients being monitored today, anywhere
from a million to a million and a half on
a given day with our healthcare partners.
Like we know what works, um,
in managing hypertension.
We know what works in
managing obesity, et cetera.
Uh, so we have formed, um, you know,
our Part B, uh, medical group and what
we're building out, and we'll announce
our clinical leadership as well.
But what we're building out is a.
A care model that's focused on
being this new layer of care.
And this is where I spend a lot of
my time, Kevin and Martin, thinking
about with our a CO partners, is
where does our care begin and where
do we bring it back to you guys?
And that, that's why I'm kind of
urging the full access cohort is,
Hey, don't go at it alone guys.
Because if, if we, if participants
start going at it alone, we're
going to create friction with the
ACOs, with the health systems.
And I think that's how the pilot fails.
I'm like really urging participants to
really think about how you integrate
back, how you coordinate back with
the ACOs, with the health systems.
Martin: I, I think that's one
of the things that I'm most
fascinated by is what, you know,
how ACOs are thinking about this.
Yeah.
How those conversations
with ACOs are going.
Um, I'd be curious if you can
kind of give us any sort of Yeah.
Initial reflections or
reactions from the, the sort of.
Withings plus an a CO on, on
what this could look like.
Patrick: Yeah.
Uh, this is where I'm
spending like all my time.
Uh, it's really exciting.
I love it.
I think it's like this is the evolution.
Um, RPM was like a false start
in hindsight, uh, all things
considered for this purpose.
The, so today we have a number
of a CO partners doing remote
management of heart failure,
hypertension, obesity, c management.
Most of the conversation today is
how do we work together to avoid
possible fragmentation of care?
That's the number one
focus today, and we are.
Operating from a place of,
okay, how do we ensure that a
patient is one, has the choice?
'cause this is really the core pillar and
as you guys, we didn't speak about this,
but the thing I'm most excited about with
access isn't the outcomes-based payment.
I think that's kind of table
stakes for this movement.
It's patient choice.
Um, the idea that a patient's benefits
isn't limited by who the payer has
contracted with and is a complete
open kind of app store approach to the
benefit, I think is transformational.
And I think other payers
will probably follow suit.
Um, but that patient choice
also means that there's a
risk of fragmentation of care.
For a PCP.
Um, so you might have a, you know,
a patient panel if you're, you
know, a thousand, 1500 patients
and then they're in, you know, a
couple hundred different programs.
Um, they themselves, right?
And that's very complicated.
So how do we preserve patient choice, but
also ensure that, um, we're coordinating
back in a way that doesn't create friction
with PCPs and, and, you know, hinder
the growth of the access, uh, pilot.
Kevin: Picking up on that choice,
one of the, one of the prerequisites
in that is awareness, and that's
been a big part of the topic of
conversation with access, is how is
the program actually driving awareness
of these decisions with patients?
How with Withings in the installed
base you already have, I would
imagine that creates a channel to go.
Create awareness within that.
But I, I'd be interested in how are
you thinking about driving awareness?
Do you expect, like, are the 65 plus
population gonna be getting flyers in the
mail starting on July 5th, being like,
Hey, you know, come use us in access.
Or like, what does, what does this
feel like as a program goes live
from an awareness perspective?
Patrick: You know, I'll tell you, uh,
we're still thinking about the playbook.
We're, we're, I, there's a lot of gray
area in Medicare marketing because a
lot of it's been written for Medicare
Advantage and we're trying to get clarity
and about, uh, what meets the intent here.
But I'll tell you what we want to
avoid is, you know, the 9:00 PM you're
watching, you know, C-N-N-M-S-N-V-C,
Fox News and you get a commercial
for Whiting saying scan QR code.
Like, we're trying to avoid that.
'cause I think that's where
this pilot access model falls
apart is that type of behavior.
Um, you know, from an
awareness perspective.
We're thinking about, you know, how
we can best serve our consumer base.
We ran a couple surveys with our
65 plus population and you know, we
have a, I think over a million to
2,000,065 plus in our consumer base.
And, you know, the number one
thing they're looking for is
actually hypertension management
Martin: really.
Patrick: And that's across,
you know, scales, blood
pressure cuffs, uh, wearables.
They're looking for help
with their hypertension.
And that's great and we can offer that.
But we also think about it like,
hey, the number one most impactful
intervention for a patient.
Sure.
Coming into access is great.
We need to get you to a PC.
You know what I mean?
Like, we need to get you in front
of A PCP and we can help you with
that and then come into access.
So I, the more we think about this,
the more we think it, that the point of
access is for tech companies, like with
things to come to the table and have,
you know, place our chips on the table.
Like, hey, we're at risk on the outcome.
But this only works if we have other
stakeholders at the table saying,
Hey, I am accountable to total cost of
care and I'm thinking about the full,
you know, care plan of this patient.
We think we have to come at it, uh,
as a team with the rest of the market.
Martin: One of the things that I find
fascinating about the access model
is CMS has lined up a bunch of payers
in the commercial space and Medicaid
space and ma space to commit to, in
principle, to a similar payment model.
I realize that the access model hasn't
rolled out in the original cohort yet.
I'd be curious though, you know, you
mentioned one or 2 million on, uh, on the
65 plus, but there's also probably a lot
of commercial folks and when I look around
my gym, I see folks with livings watches.
Uh, what, what, what, how are you thinking
about the commercial market for this?
Patrick: If I'm a payer,
why would I not do access?
Obviously it has to be successful, right?
But it's inherently deflationary, right?
Um, and you're solving for a huge burden,
which is contracting for benefits.
Um, if I'm a payer, this is
very attractive, I think.
I think a lot of this comes back to,
is it gonna work from a, you know,
how does, how do access participants
work with a provider network?
Um, and I think it's gonna be a lot
of the, a lot of the relationship.
Um, yeah, I mean we, we obviously would
invite this to grow to other payers.
Um, and it'll be the same approach, right?
Where we have an embedded consumer base,
we have, you know, uh, partnerships with
health systems ACOs, who are also managing
commercial ACOs, managing employer
sponsored programs, and being able to, um,
to, you know, do the access model there.
But we're really thinking about
the first participation period, the
first period performance period.
And, you know, coming back to, we wanna
ensure that the full model is successful.
I think another thing that's like
piggybacking access really closely,
and maybe this is the, the true purpose
of access in the market is gonna be.
You know, CMS balance and the
expansion of GLP ones starting July.
I know Kevin, we spoke
about this a few weeks ago.
Two, and you know, as we can anticipate,
you know, why distribution of GLP
ones to a senior population that
has frailty and risk of falls and,
and other adverse events, things
like access might be part of the
infrastructure, um, for that population.
I think of remote monitoring and
technology, device centric care as
being great with paired with medication
management paired for medication safety.
So I think there's a lot of value in
the commercial population, but I'm
really, really focused right now on
that first performance year and what
is access as a new layer of care.
'cause it really is something new and
defining that with the rest of the market.
Kevin: I am curious to go back to
the survey you mentioned, Patrick,
and the data you talked about on, on
patients and I, I, um, I'd be in, so
hearing that there is such an interest
in, in hypertension management, I
immediately start to wonder what is
the relationship with A PCP like today?
Yeah.
Like I, I, I hear, you know, one of the,
the veins of pushback I hear against
access and, and thinking about using
technology in this way is displacing
the relationship between somebody and
their PCP and concerns around that.
And, um, what that all implies.
But when I, when I hear that from
the survey results, I'm like,
how close are relationships do
these people have with PCPs today?
And what does that really look like?
I, I'd be, I'd be curious, any
reflections from the survey, things
you heard from that, lessons learned
about what the state of that actually
looks like in the Medicare population
using your guys' devices right now?
Patrick: Yeah, that's a great, we
don't have that direct data, but that's
where we need to be thinking about.
Right Kevin?
It's, you know, and I think that's
how we're trying to, at least
Withings is access participation
is being defined by how we augment
as a new layer of care for the pcp.
Kevin: Yep.
Patrick: And I think this could, I
think access is also kind of like a, a
new tool in the toolbox for an A CO to
be doing a better a CO lead program.
Or if you're doing ambulatory
specialty model, here's a layer of
digital care you can add on top of it.
So I really think of it as
being more like a utility.
Like I think the core principle,
at least what gets me excited every
morning, I'm up every morning just
ready to go because I think of it
as like we're providing patients
this new, always on level of care.
The assumption is that everyone
with a chronic condition should get
some level of support day to day.
Mm-hmm.
And much like we give people
electricity while their heat.
Let's get some, give them a layer
of care that's gonna be with them
and, but we can't replace the PCP.
Um, that's, and that's, I think
it's really important that the, the
broader access cohort, um, uh, be
respectful of that relationship.
Martin: Patrick, this
has been hugely helpful.
We will definitely have you
back once things get kicked off.
Awesome.
So you can share how things are going.
In the meantime.
If I lead an a CO and I wanna
work with Withings, what's the
best way for me to get in touch?
Patrick: Yeah, always.
Um, visit our website.
We have a professionals page as
well, but otherwise, feel free
to reach out, uh, to me directly.
Uh, first name, last name,
Patrick amp winnings.com.
Uh, you know, very transparently,
I think what the mar, what
ACOs are enjoying about.
Talking and working with things is that
there's no playbook that's been built
and we are trying to build it with them.
Uh, and um, it's been a very
exciting few months to say the least.
Martin: I can only imagine.
Sure.
Thanks so much, Patrick.
Kevin: Yep.
Patrick: Thanks guys.
Kevin: Good.
Patrick: Take care.
Kevin: You know, Martin, I feel like, you
know, the feedback we hear from digital
health circles coming out of access these
days is like, how, how does this all work?
And I think we just heard the
narrative of how it might work, right?
Like when I think about the insurgents
for the incumbents conversation,
I think we found the insurgent.
Martin: Yeah.
I also think, you know, you,
you have this funny, we, we.
When we're communicating about
things like this, we tend to think
of them in very two dimensional ways.
It's like, well, someone with a whitings
device is probably not going to be the
sickest highest acuity or whatever.
But you do have this interesting mix where
it's like you have Whitings customers
who are worried about hypertension,
who are having this, have this tool.
They like gone out and done this tool.
Like,
Kevin: yeah,
Martin: it would be great if they
were not, you know, clogging up the
cardiologist's, their cardiologist's
schedule, and instead we're working
with Withings and their a CO.
And I don't know, I, I, I think that some
of the, the criticism I've heard is, uh,
it feels like sour grapes basically, after
that conversation with Patrick, I'm, I'm
even more amped for, for what they've got.
Kevin: Yeah, I, I mean,
I, I think it's great.
I'm excited to see it roll out.
Let's go.
Martin: One thing I wanted to ask you
about before we go, there's been a couple
funding runs this week, uh, about risk
adjustment and risk adjustment startups.
Was not, did not have that on my
Bingo card in the last year of V 28.
And so curious for your
sort of reflections here.
Kevin: Yeah.
So we saw, um, Kepler Health got $16
million, uh, flare capital of the round
it's AI platform using clinical care.
First use case is risk adjustment purpose,
broadly speaking, it's, um, trying to
support population health use cases.
Listen, I I think it's a, it's an
evolution in the market, right?
We've had a lot of conversations recently
about risk adjustment and clinical
care and the opportunity for AI there.
And I think this is a reflection
of that and I think we're gonna be
talking a lot in the coming months,
years as we already have been now.
Um, coming outta payers
earnings call recently about.
What is actually underlying
that and digging into that.
I am, I, I would, I would hazard a
guess that Keebler would make a, a
good case on a show like this, that
it is not actually upcoding or, um,
things you might not wanna design for.
It's actually capturing
what's happening in the visit.
And I think that is a fascinating
question to think about.
Joyful Health, the other funding round
that we covered this week, they raised
22 million bucks as a revenue cycle tool
that helps providers capture revenues.
So adjacent space.
Um, in many ways, and I thought it was
interesting 'cause they're, I think it
was their funding announcement mentioned
that providers are losing out on 125
billion a year of earned revenue.
As I hear that, I mean that 125 billion
is what, like, that's a half a percent
of GDP or something like that itself.
Like it's a huge number, but
it's actually like, okay.
Providers have not been capturing what
they earned, um, effectively pre ai.
And now AI is actually
introducing that tooling in.
And there's, it, it feels like there's
an answer to this question underlying
it of like what actually happens in the
visit and what is earned versus what is
additional capture that we're all gonna
be waiting into moving forward, whether
or not we want to, and payers are gonna
need to catch up on the tail end of
this, whether or not they want to, right?
It's a brave new world we're entering.
Martin: Truly.
I mean, this is, I guess, one place where
we have seen productivity improvements
as a result of AI on earnings calls.
Is hospitals volume flat to flattish, but
revenue per patient or admission going up?
Like that's a productivity
improvement, right?
If you're getting more money for the
same, the same volume of patients and.
That's something we're
gonna have to deal with.
'cause that's inflationary.
That means we're spending
more money on healthcare.
Kevin: And the question is like, what
does a productivity improvement mean?
Like, nothing might actually be changing
in the, in the real world, it's just
there was inefficiency in how previous
errors of billing systems captured
what happened in the real world, right?
Like we see this a little bit with that
sepsis case in Massachusetts that we were
talking about a few weeks back of sepsis
diagnoses are going through the roof.
Payers are upset about that.
What's going on underlying that?
And there's this question of like, is
anything changing in the real world
or are we just capturing differently
to data differently to reflect that?
And I, I don't know the answer to that.
Um, it's gonna be interesting
to watch that evolve.
I know that.
Martin: Yeah.
So well, I feel like that's a,
a good place for us to end it.
Kevin, thanks for your time today.
Kevin: Fun as
Martin: always.
Talk to.